Conjugated oestrogens (Premarin)
Conjugated oestrogens
Pfizer Laboratories (Pty) Ltd
Registration
- Applicant
- Pfizer Laboratories (Pty) Ltd
- Registrations
- 5
Variants
| Product | Strength and form | Registration | Status | Schedule | Leaflets |
|---|---|---|---|---|---|
| Premarin 1,25 EACH TABLET CONTAINS CONJUGATED OESTROGENS 1,25 mg | 1,25 | G3014G/21.8.1/3014 | Registered | Not determined | None |
| Premarin 0,625 EACH TABLET CONTAINS CONJUGATED OESTROGENS 0,625 mg | 0,625 | G3015G/21.8.1/3015 | Registered | Not determined | None |
| Premarin 0,3 EACH TABLET CONTAINS CONJUGATED OESTROGENS 0,3 mg | 0,3 | G3016G/21.8.1/3016 | Registered | Not determined | None |
| Premarin injection EACH VIAL CONTAINS CONJUGATED OESTROGENS A 25,0 mg | Injection | G3017 | Cancelled | Not determined | None |
| Premarin cream 0,625 MG EACH 1,0 g CREAM CONTAINS CONJUGATED OESTROGENS A 0,625 mg | 0,625 mgCream | G3019 | Old Medicine | Not determined | None |
Regulatory status
This product is still scheduled by law even when this site could not determine which tier it falls under. The label carries the S number in a square border; ask a pharmacist if you need to know its schedule.
This is an informational summary of the Medicines and Related Substances Act 101 of 1965 and its 2017 General Regulations. It is not medical advice and not legal advice. Always check the medicine's label, which carries the schedule number inside a square border, or ask a pharmacist if you are unsure.
No structure available
This product's active ingredient could not be matched to a single known compound.
SAHPRA documents
SAHPRA has not published a professional information or patient information leaflet for this product.